Krystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of Medicine

• Krystal Biotech Inc (NASDAQ: KRYS) announced that data from the pivotal Phase 3 (GEM-3) trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa (DEB) had been published in the New England Journal of Medicine (NEJM).

• The 31-patient study showed complete wound healing at six months occurred in 67.4% of B-VEC wounds compared to 21.6% for placebo.

• Related: Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles.

• Complete wound healing at three months occurred in 70.6% of the wounds exposed to B-VEC compared to 19.7% of those exposed to placebo.

• The FDA accepted the marketing application for B-VEC under the Priority Review designation, and the Prescription Drug User Fee Act action date is February 17, 2023.

• Price Action: KRYS shares closed at $77.65 on Wednesday.

See more from Benzinga

• Reviva Pharmaceuticals' Schizophrenia Candidate Shows Favorable Drug-Drug Interaction Data

• Pharming Highlights Interim Data From Rare Immune Deficiency Study

• Elon Musk Says Taking Legal Action Against Jet Tracker After Son X's Car Intercepted By 'Crazy Stalker'

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.